Helius Medical Technologies, INC 8-K filings

Solana Company has amended its sales agreement to increase its at-the-market equity offering capacity to $250 million.

Solana Company stockholders elected six directors and ratified the appointment of CBIZ CPAs P.C. as the independent auditor for 2026.

Solana Company announced the completion of a registered direct offering, raising approximately $7.9 million in net proceeds to fund its digital asset treasury and general corporate purposes.

Solana Company reports the mutual agreement for Dr. Antonella Favit-Van Pelt to resign as Chief Medical Officer, effective April 8, 2026, with a separation agreement including a $875,000 payment.

Solana Company announced the appointment of Madelene Gani as Chief Operating Officer and Deputy Chief Financial Officer, effective April 6, 2026, to drive growth and institutionalize the ecosystem.

Solana Company reported a significant net loss of $352.8 million for Q3 2025, primarily driven by non-cash charges related to its new digital asset treasury strategy.

Solana Company announced significant board and executive changes, including a new Hong Kong CEO, alongside a new $100 million stock repurchase program.

Solana Company, a digital asset treasury focused on Solana (SOL), released an investor update highlighting SOL's accelerating adoption and announced the election of Pantera Capital's Cosmo Jiang to its Board of Directors.

Solana Company's stockholders approved the election of a new director, share issuances for strategic warrants and cryptocurrency-based financing, and an increase in the equity incentive plan.

Solana Company announced an increase in its SOL token holdings and reported an industry-leading staking yield, outperforming benchmarks.

Solana Company's Executive Chairman affirms commitment to long-term strategy and investor transparency by proceeding with share resale registration despite market volatility.

Solana Company announced the immediate resignation of Baker Tilly US, LLP as its auditor and the appointment of CBIZ CPAs P.C., following Baker Tilly's reports expressing substantial doubt about the company's ability to continue as a going concern.

Helius Medical Technologies, Inc. has officially changed its name to Solana Company and announced a strategic pivot to a digital asset treasury model focused on SOL, including a non-binding letter of intent with the Solana Foundation.

Helius Medical Technologies submitted its PoNS device for FDA 510(k) label expansion for chronic stroke symptoms while also granting significant cash bonuses to its CEO and CFO.

Helius Medical Technologies, Inc. announced its first acquisition of Solana (SOL) tokens, holding over 760,190 SOL, as part of a new digital asset treasury strategy.

Helius Medical Technologies has closed a private placement raising over $500 million to pivot its treasury strategy to Solana's native cryptocurrency, SOL.

Helius Medical Technologies, Inc. has entered into a new sales agreement to offer and sell up to $92.8 million of its Class A common stock through an at-the-market offering.

Helius Medical Technologies announces an oversubscribed private placement raising over $500 million, pivoting to a Solana digital asset treasury strategy.

Helius Medical Technologies, Inc. announced positive outcomes from its Portable Neuromodulation Stimulator (PoNS) Stroke Registrational Program, meeting primary endpoints for gait and balance improvement and confirming good tolerability, leading to a planned FDA submission.

Helius Medical Technologies, Inc. announced it has fully regained compliance with all Nasdaq listing requirements, including the minimum bid price and stockholders' equity rules, though it remains under a one-year mandatory monitoring period.

Helius Medical Technologies, Inc. has filed an updated prospectus supplement to offer and sell up to $25 million of its Class A Common Stock through an at-the-market offering to fund working capital and general corporate purposes.

Helius Medical Technologies, Inc. has filed an 8-K announcing a 1-for-50 reverse stock split, effective June 30, 2025, to meet Nasdaq's continued listing requirements.

Helius Medical Technologies, Inc. announced it has regained compliance with Nasdaq's minimum stockholders' equity requirement following a recent public offering that raised approximately $8.1 million.

Helius Medical Technologies, Inc. announced an increase in the aggregate number of shares available under its 2022 Equity Incentive Plan to 7.1 million shares, following stockholder approval and the closing of a public offering.

Helius Medical Technologies, Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement, though it still needs to meet the equity rule by June 30, 2025.

Helius Medical Technologies, Inc. announced that its stockholders approved a reverse stock split, an increase in authorized shares, and the issuance of shares for a potential financing at a special meeting on May 23, 2025.

Helius Medical Technologies will implement a 1-for-15 reverse stock split, effective May 1, 2025, to meet Nasdaq's continued listing requirements.

Helius Medical Technologies enters into a securities purchase agreement for a private placement, raising $1.3 million to support working capital and general corporate purposes.

Helius Medical Technologies held its annual meeting of stockholders on April 21, 2025, and voted on the election of directors, ratification of the accounting firm, approval of a warrant inducement share issuance, approval of a reverse stock split, and authorization of meeting adjournments.

Helius Medical Technologies receives notice from Nasdaq regarding non-compliance with minimum stockholders' equity requirement and is granted an extension until June 30, 2025, to regain compliance.